Solid-State Upadacitinib for Oral Control of GCA and RA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Janus kinase-associated conditions such as rheumatoid arthritis and vasculitis, particularly giant cell arteritis, are cumbersome and often require long-term corticosteroid use, leading to potential relapses and patient inconvenience.
Innovation Solution
Administration of a therapeutically effective amount of a solid-state form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (upadacitinib) in various dosages, optionally combined with other therapeutic agents, to treat these conditions, providing an oral alternative to corticosteroids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long-term corticosteroid use is employed to treat Janus kinase-associated conditions, then anti-inflammatory effects are achieved, but patient convenience deteriorates and relapse risk increases
Solution Approach 1:
The patent changes the pharmacological parameter from corticosteroid-based anti-inflammatory mechanism to JAK1 inhibitor-based mechanism, achieving comparable therapeutic effects with improved patient convenience through once-daily oral administration and reduced relapse risk upon discontinuation
2Reliability
If long-term corticosteroid use is employed to treat Janus kinase-associated conditions, then anti-inflammatory effects are achieved, but relapse risk increases upon discontinuation
Solution Approach 1:
The patent changes the pharmacological parameter from corticosteroid-based anti-inflammatory mechanism to JAK1 inhibitor-based mechanism, achieving comparable therapeutic effects with reduced relapse risk upon discontinuation due to the drug's favorable pharmacokinetic profile and lack of adrenal suppression
3Ease of operation
If oral therapeutic alternatives to corticosteroids are developed, then patient convenience is improved, but therapeutic efficacy must be maintained
Solution Approach 1:
The patent changes the pharmacological parameter from corticosteroid-based anti-inflammatory mechanism to JAK1 inhibitor-based mechanism, maintaining therapeutic efficacy in treating Janus kinase-associated conditions while improving patient convenience through once-daily oral administration
Solution Approach 2:
The patent substitutes the corticosteroid molecular mechanism with a JAK1 inhibitor molecular mechanism, achieving similar clinical outcomes while providing the advantage of oral administration and reduced side effects
Data Source
AI summary
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and vasculitis), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating giant cell arteritis (GCA).